Literature DB >> 30869653

New epitopes in ovalbumin provide insights for cancer neoepitopes.

Sukrut Hemant Karandikar1, John Sidney2, Alessandro Sette2, Mark Joseph Selby3, Alan Jerry Korman3, Pramod Kumar Srivastava1,4.   

Abstract

MHC I-restricted epitopes of chicken ovalbumin (OVA) were originally identified using CD8 T cells as probes. Here, using bioinformatics tools, we identify four additional epitopes in OVA in addition to a cryptic epitope. Each new epitope is presented in vivo, as deduced from the lack of CD8 response to it in OVA-transgenic mice. In addition, CD8 responses to the known and novel epitopes are examined in C57BL/6 mice exposed to the OVA-expressing tumor E.G7 in several ways. No responses to any epitope including SIINFEKL are detected in mice with growing E.G7 or mice immunized with the tumor. Only in E.G7-bearing mice treated with an anti-CTLA4 antibody which depletes tumor-infiltrating regulatory T cells, CD8 responses to SIINFEKL and the novel epitope EKYNLTSVL are detected. Finally, all epitopes fails to treat mice with pre-existing tumors. These observations force an important re-consideration of the common assumptions about the therapeutic value of neoepitopes detected by CD8 responses in tumor-bearing hosts.

Entities:  

Keywords:  Antigen presentation; Cancer immunotherapy; Cellular immune response; Immunology

Year:  2019        PMID: 30869653      PMCID: PMC6538383          DOI: 10.1172/jci.insight.127882

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  18 in total

1.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

2.  Immunological speculations.

Authors:  N K JERNE
Journal:  Annu Rev Microbiol       Date:  1960       Impact factor: 15.500

3.  Exact prediction of a natural T cell epitope.

Authors:  O Rötzschke; K Falk; S Stevanović; G Jung; P Walden; H G Rammensee
Journal:  Eur J Immunol       Date:  1991-11       Impact factor: 5.532

4.  Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture.

Authors:  John Sidney; Scott Southwood; Carrie Moore; Carla Oseroff; Clemencia Pinilla; Howard M Grey; Alessandro Sette
Journal:  Curr Protoc Immunol       Date:  2013-02

5.  MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope.

Authors:  K el-Shami; B Tirosh; E Bar-Haim; L Carmon; E Vadai; M Fridkin; M Feldman; L Eisenbach
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

Review 6.  Pathways of antigen processing.

Authors:  Janice S Blum; Pamela A Wearsch; Peter Cresswell
Journal:  Annu Rev Immunol       Date:  2013-01-03       Impact factor: 28.527

7.  The ovalbumin serpins revisited: perspective from the chicken genome of clade B serpin evolution in vertebrates.

Authors:  Charaf Benarafa; Eileen Remold-O'Donnell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-29       Impact factor: 11.205

8.  Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.

Authors:  Mark J Selby; John J Engelhardt; Michael Quigley; Karla A Henning; Timothy Chen; Mohan Srinivasan; Alan J Korman
Journal:  Cancer Immunol Res       Date:  2013-04-07       Impact factor: 11.151

9.  A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection.

Authors:  Erika Assarsson; John Sidney; Carla Oseroff; Valerie Pasquetto; Huynh-Hoa Bui; Nicole Frahm; Christian Brander; Bjoern Peters; Howard Grey; Alessandro Sette
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

10.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.

Authors:  Fei Duan; Jorge Duitama; Sahar Al Seesi; Cory M Ayres; Steven A Corcelli; Arpita P Pawashe; Tatiana Blanchard; David McMahon; John Sidney; Alessandro Sette; Brian M Baker; Ion I Mandoiu; Pramod K Srivastava
Journal:  J Exp Med       Date:  2014-09-22       Impact factor: 14.307

View more
  7 in total

1.  Technical choices significantly alter the adaptive immune response against immunocompetent murine gliomas in a model-dependent manner.

Authors:  Breanna Noffsinger; Alexandra Witter; Natasha Sheybani; Aizhen Xiao; Laryssa Manigat; Qing Zhong; Suchet Taori; Tajie Harris; Tim Bullock; Richard Price; Benjamin Purow
Journal:  J Neurooncol       Date:  2021-08-25       Impact factor: 4.506

2.  Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.

Authors:  A J Robert McGray; Ruea-Yea Huang; Sebastiano Battaglia; Cheryl Eppolito; Anthony Miliotto; Kyle B Stephenson; Amit A Lugade; Gill Webster; Brian D Lichty; Mukund Seshadri; Danuta Kozbor; Kunle Odunsi
Journal:  J Immunother Cancer       Date:  2019-07-17       Impact factor: 12.469

Review 3.  Nanocarrier-Based Drug Delivery for Melanoma Therapeutics.

Authors:  Mingming Song; Chang Liu; Siyu Chen; Wenxiang Zhang
Journal:  Int J Mol Sci       Date:  2021-02-13       Impact factor: 5.923

4.  A Combined Adjuvant TF-Al Consisting of TFPR1 and Aluminum Hydroxide Augments Strong Humoral and Cellular Immune Responses in Both C57BL/6 and BALB/c Mice.

Authors:  Qiao Li; Zhihua Liu; Yi Liu; Chen Liang; Jiayi Shu; Xia Jin; Chuanyou Li; Zhihua Kou
Journal:  Vaccines (Basel)       Date:  2021-11-29

5.  Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer.

Authors:  Peter M K Westcott; Nathan J Sacks; Jason M Schenkel; Zackery A Ely; Olivia Smith; Haley Hauck; Alex M Jaeger; Daniel Zhang; Coralie M Backlund; Mary C Beytagh; J J Patten; Ryan Elbashir; George Eng; Darrell J Irvine; Omer H Yilmaz; Tyler Jacks
Journal:  Nat Cancer       Date:  2021-09-30

6.  Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines.

Authors:  Ifeanyi Kingsley Uche; Brent A Stanfield; Jared S Rudd; Konstantin G Kousoulas; Paul J F Rider
Journal:  Front Mol Biosci       Date:  2022-01-26

7.  Systemic inhibition of PTPN22 augments anticancer immunity.

Authors:  Won Jin Ho; Sarah Croessmann; Jianping Lin; Zaw H Phyo; Soren Charmsaz; Ludmila Danilova; Aditya A Mohan; Nicole E Gross; Fangluo Chen; Jiajun Dong; Devesh Aggarwal; Yunpeng Bai; Janey Wang; Jing He; James M Leatherman; Mark Yarchoan; Todd D Armstrong; Neeha Zaidi; Elana J Fertig; Joshua C Denny; Ben H Park; Zhong-Yin Zhang; Elizabeth M Jaffee
Journal:  J Clin Invest       Date:  2021-07-20       Impact factor: 19.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.